Form 4: InspireMD Director Granted 44,030 Restricted Shares

InspireMD, Inc. Director Danny L. Dearen received a grant of 44,030 restricted common stock shares, which are set to vest on January 14, 2027.

Summary

• Danny L. Dearen, a Director of InspireMD, Inc. (NSPR), acquired 44,030 shares of common stock.
• These shares are restricted stock and were granted at a price of $0 per share.
• The shares are scheduled to vest on January 14, 2027, contingent upon Mr. Dearen's continued service to the company.
• Following this transaction, Mr. Dearen beneficially owns 102,047 shares of common stock.
• The transaction date for the acquisition was January 14, 2026.

Sentiment

Score: 6

Explanation: Slightly positive. An insider receiving an equity grant aligns their interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of restricted stock to Director Danny L. Dearen aligns his interests with those of shareholders, as the value of his compensation is tied to the company's future stock performance.
• The vesting schedule encourages long-term commitment and continued service from a key director.

Risks

• The value of the restricted stock grant is subject to market fluctuations; if InspireMD, Inc.'s stock price declines before the vesting date, the actual value realized by the director will be lower than the grant date value.
• The shares are subject to forfeiture if the reporting person's service to the company ceases before the vesting date.

Future Outlook

The 44,030 restricted shares granted to Director Danny L. Dearen are scheduled to vest on January 14, 2027, contingent on his continued service to InspireMD, Inc.

Industry Context

This is a routine insider compensation event common across publicly traded companies, reflecting standard practices for aligning director incentives with shareholder value. It does not provide specific insights into broader industry trends for medical devices or cardiovascular health, which is InspireMD's sector.

Comparison to Industry Standards

• Granting restricted stock to directors is a common practice in the U.S. public company landscape, aligning director incentives with long-term shareholder value, similar to compensation structures at peer medical device companies.
• The vesting period of one year is a standard duration for such grants, comparable to practices observed in companies like Medtronic (MDT) or Boston Scientific (BSX) for similar equity awards to non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of 44,030 shares of restricted common stock to Director Danny L. Dearen constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's financial interests with the company's long-term performance.

Next Steps

• Continued service of Danny L. Dearen as a Director of InspireMD, Inc.
• Vesting of 44,030 restricted shares on January 14, 2027.

Key Dates

Keywords

InspireMD, NSPR, Danny L. Dearen, Restricted Stock, Insider Transaction, Form 4, Director Compensation, Equity Grant, Stock Vesting